Cipla Release: CARE Reaffirms ‘CARE AAA / A1+’ Rating
Mumbai, January 21, 2016: Cipla is pleased to announce that the Credit Analysis and Research
Limited (CARE) has reaffirmed a ‘CARE AAA / A1+’ rating to the various bank facilities for an
aggregate amount of Rs.3310.50 crores.
CARE is the second-largest credit rating agency in India.
About Cipla Limited
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.
Cipla’s research and development focuses on developing innovative products and drug delivery systems.
For further details please contact:
Media Contacts:
Corporate Communications
Charlotte Chunawala
Mobile: +91 7506257377
E Mail: charlotte.chunawala@cipla.com;
Pallavi Golar
Mobile: +91 9833641788
E Mail: pallavi.golar@cipla.com
CARE is the second-largest credit rating agency in India.
About Cipla Limited
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.
Cipla’s research and development focuses on developing innovative products and drug delivery systems.
For further details please contact:
Media Contacts:
Corporate Communications
Charlotte Chunawala
Mobile: +91 7506257377
E Mail: charlotte.chunawala@cipla.com;
Pallavi Golar
Mobile: +91 9833641788
E Mail: pallavi.golar@cipla.com